Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRI BioGRI -1.16%28 3-Year ROIIC % is 1,609.59 as of Dec. 2025, which is 78% above its 10-year median of 903.35. GuruFocus rates GRI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,316 Biotechnology companies, GRI Bio ranks better than 95.36% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
GRI Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,609.59%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for GRI Bio's 3-Year ROIIC % or its related term are showing as below:
GRI's 3-Year ROIIC % is ranked better than 95.36% of 1316
companies
in the Biotechnology industry
Industry Median: -4.42
vs GRI: 1609.59
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
GRI Bio 3-Year ROIIC % Related Terms
GRI Bio 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for GRI Bio's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI vs ISCO, VRAX, SLXN: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, GRI Bio's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where GRI Bio's 3-Year ROIIC % falls into.
GRI Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -11.977 (Dec. 2025) - -2.239 (Dec. 2022) )
/
( 0.13 (Dec. 2025) - 0.735 (Dec. 2022) )
=
-9.738
/
-0.605
=
1,609.59%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
GRI Bio (GRI) has a 3-Year ROIIC % of 1,609.59 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on GRI Bio and its competitors. This is 78% above median its historical median of 903.35. Over the past decade, GRI Bio's 3-Year ROIIC % has ranged from 197.11 to 1,609.59. According to the industry distribution chart, GRI Bio ranks #61 out of 1316 companies in the Biotechnology industry, placing it in the top 4.6%.
Is GRI Bio's 3-Year ROIIC % too high?
GRI Bio's current 3-Year ROIIC % of 1,609.59 is 78% above median its 10-year median of 903.35. Over the past 10 years, this metric has ranged from a low of 197.11 to a high of 1,609.59. Based on the distribution chart, GRI Bio ranks #61 out of 1316 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GRI Bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's 3-Year ROIIC % compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #61 out of 1316 companies for 3-Year ROIIC %. This places GRI Bio in the top 5% of its industry — outperforming the majority of peers. Historically, GRI Bio's own 3-Year ROIIC % has ranged from 197.11 to 1,609.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on GRI Bio and its competitors. GRI Bio's current 3-Year ROIIC % is 1,609.59, which is 78% above median its own 10-year median of 903.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current 3-Year ROIIC % of 1,609.59. The current 3-Year ROIIC % is 1,609.59, which is 78% above median its 10-year median of 903.35. GRI Bio's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For GRI Bio (GRI), the current 3-Year ROIIC % is 1,609.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
28GF Score
Get the complete analysis for GRI
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRI has been successfully added to your 
